- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Questionnaire Administration, Selvigaltin
- Procedure · Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Buffalo, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 170
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Stiff Person Syndrome
- Interventions
- VYVGART Hytrulo, Hytrulo-placebo (consisting of Hyaluronidase)
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 25 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Healthy Volunteers
- Interventions
- TAK-881
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Hialeah, Florida
- Conditions
- Drug Hypersensitivity
- Interventions
- Vitrase
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Davis, California
- Conditions
- Mass Casualty Incident, Dehydration
- Interventions
- hypodermoclysis via recombinant hyaluronidase-facilitated subcutaneous infusion
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Rapid Acting insulin with pre-treatment of rHuPH20, Sham injection
- Drug · Device
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- HER2-Positive Early Breast Cancer
- Interventions
- Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC), Pertuzumab IV, Trastuzumab IV
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 9
- States / cities
- Lakewood, Colorado • Peoria, Illinois • Wichita, Kansas + 5 more
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide
- Drug
- Lead sponsor
- Eden Biltibo
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Plasma Cell Leukemia
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Fludeoxyglucose F-18, Lenalidomide, Magnetic Resonance Imaging, Melphalan, Plerixafor, Positron Emission Tomography, Recombinant Granulocyte Colony-Stimulating Factor, Stem Cell Isolation, Teclistamab, Transthoracic Echocardiography Test
- Procedure · Drug · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 11
- States / cities
- La Jolla, California • New Haven, Connecticut • North Haven, Connecticut + 8 more
- Conditions
- Diabetes Mellitus
- Interventions
- Insulin Lispro, Regular Human Insulin, rHuPH20
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Atezolizumab and Recombinant Human Hyaluronidase, Survey Administration
- Biological · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Ixazomib, Pomalidomide, Dexamethasone, Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 4
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 1 more
- Conditions
- Type 1 Diabetes
- Interventions
- ePID closed loop system, hyaluronidase, Lispro-PH20
- Device · Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 12 Years to 40 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Amyloid Light-chain Amyloidosis
- Interventions
- Teclistamab, Daratumumab and Hyaluronidase-fihj
- Drug
- Lead sponsor
- Rajshekhar Chakraborty, MD
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Milwaukee, Wisconsin
- Conditions
- Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance
- Interventions
- Daratumumab and hyaluronidase-fihj
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Hackensack, New Jersey
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab Subcutaneous (SC) Administration, Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 1 more
- Conditions
- IgG4-related Disease
- Interventions
- Efgartigimod
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell, Myeloma-Multiple, Myelomatosis, Plasma Cell Myeloma
- Interventions
- Selinexor, Dexamethasone Oral, Daratumumab, Lenalidomide
- Drug
- Lead sponsor
- US Oncology Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Denver, Colorado • Columbia, Maryland + 7 more
- Conditions
- Superficial Bladder Cancer
- Interventions
- Chemophase
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Anaheim, California • La Mesa, California + 2 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20), Liquid meal
- Drug · Other
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreatic Neoplasms
- Interventions
- PEGPH20, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Pancreatic Cancer Research Team
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- Gilbert, Arizona • Los Angeles, California • New Brunswick, New Jersey + 2 more
- Conditions
- Diabetes Mellitus
- Interventions
- Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Primary Immunodeficiency Diseases (PID)
- Interventions
- TAK-881, HYQVIA
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 15
- States / cities
- Irvine, California • Walnut Creek, California • Denver, Colorado + 12 more